A meta-analysis by Zhao et al. showed significantly shortened overall survival in head and neck cancer patients with CXCR4 expression (7 studies, 577 patients, HR = 2.02, 95% CI, 1.37–2.97) [15]. Here, CXCR4 is linked to head and neck cancer.